Lunchables, Capri Sun… and a skinny jab?

GLP-1 weight loss drugs may soon be coming for first graders, with new research from the makers of Ozempic and Wegovy finding that kids between 6 and 11 lost significant weight on the drug, which protects them from serious obesity-related health problems down the line.

But parents may want to think twice about seeking a prescription for junior: In addition to weight loss, they found that semaglutide use in young kids also produced a troubling side effect.

Novo Nordisk’s new research found that kids on semaglutide (sold as Wegovy) lost weight but also grew over an inch less than kids who were not on the drug.

Doctors say it’s unclear how this will affect their adult height, and that’s one of many questions left unanswered about giving these drugs to kids this young.

Lowering weight, improving health?

In the US, obesity is exploding among very young children. One in five US children have it, and GLP-1s are already approved to treat kids as young as 12.

Legally, doctors can give GLP-1 scrips off-label to kids aged 8 to 11 in extraordinary circumstances — and data shows docs are writing a jaw-dropping 310 times more scrips for this age group than they were just a few years ago.

Now, Novo Nordisk is hoping data from their new clinical trial can pave the way for the drug to be officially approved for kids as young as 6. With the new evidence, they plan to ask the FDA to approve the drug in kids in this age group in 2027.

In the study, kids were given once-weekly semaglutide injections or placebo for two years. Both groups also received counseling for diet and exercise.

By a year and a half, 79% of the kids on semaglutide lost enough weight to be in a different BMI category, and 38% lost enough to no longer be classified as obese.

At the two-year mark, those on semaglutide dropped 9.4% in BMI. Meanwhile, placebo raised BMI 8.4% — a total difference of 17.8%.

While almost all participants taking the drug experienced side effects — most commonly gastrointestinal symptoms like nausea and vomiting, which are also common among adults on the drug — they also faced a particular growth issue.

Kids on the medication grew 1.3 inches less than those who didn’t take the drug. Kids in this age group normally grow between 4 and 5 inches over two years.

Dr. Mary Pat Gallagher, director of the Division of Pediatric Endocrinology and Diabetes at Hassenfeld Children’s Hospital at NYU Langone, told The Post that “obesity itself can affect growth. Children with overweight or obesity are often taller than their peers early in childhood, but evidence suggests they may ultimately have a modestly lower final adult height than the general population.”

We don’t know whether or how GLP-1s change that trajectory, she says. Only a follow-up study will show whether they reach expected adult height.

Still, she said, the risks associated with obesity are so significant that “the possibility of a modest height difference would not necessarily outweigh the immediate health risks of untreated disease.”

In fact, she called the overall trial results “remarkable and encouraging.”

“Semaglutide appears to be very effective at improving BMI percentile in children with obesity, which can reduce the risk of — and in some cases help treat — related conditions such as metabolic-associated liver disease, high blood pressure, and obstructive sleep apnea.

“But the growth finding is important and deserves careful, longer-term study,” she added.

One of many concerns for kids

It’s certainly a tough call to make. Research in adults shows that GLP-1s work but require continued use: Many benefits reverse if a patient stops using them. It’s possible children put on the drug will not be able to get off it without losing their progress.

“It may not mean the same medication or dose forever, but obesity is a persistent medical problem that will likely require ongoing management,” Gallagher said.

There are also concerns about kids’ muscle and bone development, including lean body mass, strength, bone mineral accrual, final height and nutrition.

In October, the World Health Organization recommended against using GLP-1s in kids under 9.

“The foundation of obesity care for children and adolescents is not medicine or surgery, but access to comprehensive support that enables healthy eating, physical activity and sustainable behaviour change,” WHO Dr. Luz María De Regil said in a statement.

Share.